Anti-CD24 antibody [EPR3006(N)]
- RabMAb
- Recombinant
- What is this?
Be the first to review this product! Submit a review
|
(23 Publications)
Rabbit Recombinant Monoclonal CD24 antibody. Suitable for IP, WB and reacts with Human samples. Cited in 23 publications.
View Alternative Names
CD24, CD24A, Signal transducer CD24, Small cell lung carcinoma cluster 4 antigen
- IP
Supplier Data
Immunoprecipitation - Anti-CD24 antibody [EPR3006(N)] (AB179821)
Western blot analysis on immunoprecipitation pellet from (1) SH-SY5Y cell lysate or (2) 1X PBS (negative control) labeling CD24 using ab179821 at 1/10 dilution, and HRP-conjugated anti-rabbit IgG preferentially detecting the non-reduced form of rabbit IgG.
All lanes:
Immunoprecipitation - Anti-CD24 antibody [EPR3006(N)] (ab179821)
Predicted band size: 8 kDa
false
- WB
Supplier Data
Western blot - Anti-CD24 antibody [EPR3006(N)] (AB179821)
All lanes:
Western blot - Anti-CD24 antibody [EPR3006(N)] (ab179821) at 1/1000 dilution
Lane 1:
fetal brain lysate at 10 µg
Lane 2:
SH-SY5Y cell lysate at 10 µg
Lane 3:
human oligodendroglioma lysate at 10 µg
Predicted band size: 8 kDa
false
- WB
CiteAb
Western blot - Anti-CD24 antibody [EPR3006(N)] (AB179821)
CD24 western blot using anti-CD24 antibody [EPR3006(N)] ab179821. Publication image and figure legend from Schloesser, D., Lindenthal, L., et al., 2023, J Cell Biol, PubMed 36459066.
ab179821 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab179821 please see the product overview.
Impairment of efferocytosis by senescent cells is mediated by CD47 and CD24 expression. (A) CD47 loss-of-function in 3T3 cells was verified by CD47 staining in flow cytometry. (B) Representative immunofluorescence images from senescent 3T3 cells (WT or CD47 KO) showing CD47 (green) and Phalloidin (blue) staining (scale bar : 50 μm). n = 2. (C) Quantification of efferocytosis of apoptotic corpses by BMDMs in the presence of CD47 KO senescent cells (induced by palbociclib). Samples were analyzed by flow cytometry. Data are representative of three independent experiments. All values are means ± SEM. Statistically significant differences were determined by one-way ANOVA with Bonferroni correction; n = 3 biological replicates. (D) Schematic overview of the experimental design. Senescent human fibroblasts were incubated with neutralizing anti-CD47 FAB fragments for 1 h, then direct co-cultures with primary macrophages were assembled for 6 h, followed by exposure to pHrodo labeled apoptotic corpses. Corpse removal was monitored by live cell imaging (IncuCyte). (E and F) Quantification of efferocytosis of apoptotic corpses in co-cultures of human MDMs and senescent primary NHLF (E) or IPF-derived fibroblast (IPF; F). Efferocytotic capability of macrophages in co-culture with senescent fibroblast in the presence (blue bar) or absence of FAB fragments (gray bar) was monitored over time using the IncuCyte S3 system. Then area under curve (AUC) from 2 to 20 h was calculated and plotted. Data are representative of three independent experiments. All values are means ± SEM. Statistically significant differences were determined by unpaired Student's t test. (G) Whole-cell lysates derived from Panc1 cells (WT and CD47 KO) were analyzed by Western blot for the indicated proteins. GAPDH was used as loading control. Senescence was induced by chemical treatment (Palbociclib). Blots are representative of three independent experiments. GAPDH image is derived from the same blot as Fig. 7 and Fig. S3. CD24 image is derived from the same blot as in Fig. S3. (H) Quantification of efferocytosis of apoptotic corpses by MDMs in the presence of senescent Panc1 cells. Efferocytotic capability of macrophages in co-culture with WT (red line) or CD47 KO (green line) Panc1 cells was monitored over time. Data are representative of at least three independent experiments. All values are means ± SEM. (I) Quantification of efferocytosis of apoptotic corpses in co-cultures of human MDMs and proliferating (black bar) or senescent CD47 KO Panc1 cells. Senescent CD47 KO cells were treated with (orange bar) or without anti-CD47 FAB fragments (green bar) prior to the assembly of the co-culture with MDMs. Efferocytotic capability of macrophages was monitored over time using the IncuCyte S3 system. Then area under curve (AUC) from 2 to 22 h was calculated and plotted. Shown values are means of at least technical triplicates ± SEM in one representative experiment. Data are representative of three independent experiments. **p < 0.01. Statistically significant differences were determined by one-way ANOVA with Bonferroni correction. (J) Quantification of efferocytosis of apoptotic corpses in co-cultures of human MDMs and proliferating (gray bar) or senescent primary small airway cells (SAEC). Senescent SEAC cells were either untreated (green bar) or treated with anti-CD47 (blue bar) or anti-CD24 FAB fragments (orange bar) or the combination of both FAB fragments (violet bar) prior to the assembly of the co-culture with MDMs. Efferocytotic capability of macrophages was monitored over time using the IncuCyte S3 system. Then area under curve (AUC) from 2 to 22 h was calculated and plotted. Shown values are means of technical quadruplicates ± SEM in one representative experiment. Data are representative of two independent experiments *p < 0.05, **p < 0.005. Statistically significant differences were determined by one-way ANOVA with Bonferroni correction. Source data are available for this figure : SourceData F8.
false
Related conjugates and formulations (1)
-
Anti-CD24 antibody [EPR3006(N)] - BSA and Azide free
Reactivity data
Product details
Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free batch production
For more information, read more on recombinant antibodies.
Properties and storage information
Form
Purity
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
CD24 functions like a molecular "switch" modulating signals sent between cells. It acts as a ligand for multiple receptors and participates in cellular communication especially influencing the immune system. Part of its biological role involves interaction within cellular complexes impacting immune modulation and inflammatory responses. CD24's location at the interface of cellular microenvironments makes it critical for cellular response adaptation to varied external stimuli.
Pathways
CD24 participates in both immune signaling and cancer-related pathways. It plays a significant role in the suppression of the immune response often interacting with proteins like Siglec-10 in these pathways. CD24's involvement in these pathways contributes to cell survival and proliferation particularly within cancer development. The protein’s interaction within specified signaling pathways allows it to influence downstream targets that regulate gene expression and cellular functions.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (23)
Recent publications for all applications. Explore the full list and refine your search
Nature communications 16:8642 PubMed41028719
2025
Applications
Unspecified application
Species
Unspecified reactive species
Journal of clinical and translational hepatology 13:15-24 PubMed39801781
2025
Applications
Unspecified application
Species
Unspecified reactive species
Journal of cancer research and clinical oncology 150:155 PubMed38526702
2024
Applications
Unspecified application
Species
Unspecified reactive species
Cell death discovery 10:81 PubMed38360723
2024
Applications
Unspecified application
Species
Unspecified reactive species
Cell & bioscience 13:176 PubMed37743465
2023
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of cell biology 222: PubMed36459066
2022
Applications
Unspecified application
Species
Unspecified reactive species
Experimental and therapeutic medicine 24:746 PubMed36561974
2022
Applications
Unspecified application
Species
Unspecified reactive species
NPJ breast cancer 8:115 PubMed36309503
2022
Applications
Unspecified application
Species
Unspecified reactive species
Journal of gastroenterology and hepatology 38:138-152 PubMed36300571
2022
Applications
Unspecified application
Species
Unspecified reactive species
Histology and histopathology 38:65-72 PubMed35856500
2022
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com